Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608595 · ClinicalTrials.gov registry record · NA
Celecoxib in Treating Patients With Early-Stage Rectal Cancer
A NA study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00608595 is a NA study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 10 participants.
The verdict
NCT00608595, a NA study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how rectal cancer will respond to treatment with celecoxib. PURPOSE: This clinical trial is studying how well celecoxib works in treating patients with early-stage rectal cancer.
Interventions
- GENETIC gene expression analysis
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- OTHER immunohistochemistry staining method
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2002-07 |
| Est. Completion | 2008-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00608595
The ClinicalTrials.gov registry entry for NCT00608595 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00608595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00608595 about?
NCT00608595 is a clinical study titled "Celecoxib in Treating Patients With Early-Stage Rectal Cancer". RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how rectal cancer will respond to treatment with celecoxib. ...
What is the current status of trial NCT00608595?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2002-07. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00608595?
The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), immunohistochemistry staining method (OTHER), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00608595?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.